COVID-19 rebound from Paxlovid likely due to insufficient exposure to drug - study
A clinical trial presented the drug's capabilities to reduce the risk of hospitalization and death from COVID by 89%.
Coronavirus disease (COVID-19) treatment pill Paxlovid is seen in a box, at Misericordia hospital in Grosseto, Italy, February 8, 2022.(photo credit: REUTERS/JENNIFER LORENZINI/FILE PHOTO)ByJERUSALEM POST STAFF
